Find Clinical Trials

Inclusion Criteria: * 1\. Subjects should be over 18 years old, regardless of gender. * 2\. Histologically or cytologically confirmed HR - positive, HER2 - negative advanced breast cancer. * 3\. For patients in the dose escalation stage, there are no limitation on previous treatments. The investigator must assess whether the patients are currently suitable for enrollment and eligible to receive the study drug treatment. For patients in the dose expansion stage need to meet the following criteria: The patient has received (neo)adjuvant endocrine therapy and has evidence of radiographic recurrence or progression during the treatment or within 12 months after the end of the treatment. The patient is allowed to receive no more than one line of systemic chemotherapy at the recurrence and metastasis setting. The patient has not received CDK4/6 inhibitor treatment at the recurrence and metastasis setting. * 4\. At least one measurable lesion meeting RECIST V1.1 criteria (patients with bone-only metastases may be enrolled in the dose escalation stage). * 5\. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 - 1. * 6\. The predicted survival time is more than 6 months. * 7\. The major organ functions must meet the protocol criteria within 7 days prior to treatment. * 8\. Voluntarily participate in this clinical study, understand the research procedures, and be able to sign the written informed consent form. Exclusion Criteria: * 1\. Previously diagnosed with HER2 - positive breast cancer through pathological examination. * 2\. Patients deemed by the investigator as unsuitable for endocrine therapy (e.g., those with visceral crisis posing immediate life-threatening risks in the short term, including: uncontrolled massive effusions \[pleural, pericardial, or peritoneal\], pulmonary lymphangitic carcinomatosis, or hepatic involvement \>50%). * 3\. Patients who have previously received treatment with fulvestrant or inhibitors such as PI3K/AKT/mTOR. * 4\. Patients with uncontrolled third-space fluid accumulation (e.g., pericardial effusion, pleural effusion, or ascites) requiring repeated drainage or other therapeutic interventions, and deemed ineligible for enrollment by investigators. * 5\. Patients with a history of severe lung diseases, such as interstitial lung disease and/or pneumonia, or pulmonary hypertension, or radiation pneumonia requiring glucocorticoid treatment. * 6\. Patients with chronic gastrointestinal dysfunction mainly manifested as diarrhea, such as Crohn's disease, ulcerative colitis, malabsorption, or diarrhea of grade ≥ 1; intestinal obstruction, or other gastrointestinal diseases deemed clinically significant by investigators. * 7\. Patients with known coagulation disorders such as bleeding tendency; or those who need to use anticoagulants, which may affect the intramuscular injection of fulvestrant or the use of LHRH agonists. * 8\. Patients with known hypersensitivity or intolerance to any component of the investigational drug(s), their excipients, or LHRH agonists (if applicable). * 9\. Patients with a history of autoimmune diseases (except tuberous sclerosis), immunodeficiency diseases (including positive HIV test), or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.

Inclusion Criteria: * Patients with confirmed advanced HCC (Diagnosed by two imaging modalities or liver biopsy) eligible for atezolizumab-bevacizumab therapy. * Patients with preserved liver function (compensated Child-Pugh A if there is underlying cirrhosis). * Patients with performance status ≤2 at staging work-up. * Patients with no or grade 1 non-risky esophageal varices on pretreatment endoscopic examination. Exclusion Criteria: * Child-Pugh class C patients. * Patients with performance status \>2 at staging work-up. * Vascular disorders and arterial hypertension. * Severe autoimmune disorders. * Patients who lost follow-up. * Pregnant or breastfeeding women. * Unwilling to participate in our study.

Inclusion Criteria: * Written Informed consent * Adult aged ≥18 years * English proficiency * High BP defined as home SBP ≥135 or DBP ≥85 mmHg, either untreated or receiving one or two BP lowering drugs * Among untreated individuals, indicated for pharmacological treatment of high BP according to 2023 Australian Heart Foundation Cardiovascular Risk Management Guidelines * Willing to receive BP lowering drug treatment remotely if treatment is indicated * Willing to check BP with home monitoring for 12 weeks * Willing to participate in telehealth visit at baseline and 12 weeks * Willing to undergo blood tests Exclusion Criteria: * Currently receiving three or more BP lowering drugs * Currently receiving an antihypertensive that is not one of the five major antihypertensive drug classes * Home SBP ≥155 mmHg for untreated participants * Home SBP ≥150 mmHg for participants on one BP lowering drug * Home SBP ≥145 mmHg for participants on two BP lowering drugs * Baseline eGFR \<45 ml/min/m2 * Any abnormalities on baseline electrolytes that would prevent initiation of BP lowering therapy * Participants with any other medical condition or taking any other concomitant medication which in the opinion of the investigator would make the participant unsuitable for the trial. * Of childbearing age and not using contraception. * Planned international travel for next 12 weeks

Inclusion Criteria: 1. You are male or female aged 19 to 65 years inclusive. 2. You have a diagnosis of bipolar disorder type II, and are currently in a major depressive episode. 3. You are willing, for the entire duration of the study, to practice highly effective methods of contraception (e.g., contraceptive pills, intrauterine device or system, vasectomy and tubal ligation, or double-barrier methods of contraception) OR agree to completely abstain from heterosexual intercourse. Females who do not have childbearing potential are required to be postmenopausal for at least 1 year before the screening visit (confirmed by an FSH test) OR surgically sterile. 4. You have sufficient English language skills to understand, consent to, and comply with study requirements, study visits, and to return to the clinic for follow-up evaluations. 5. Your current medications have been at a stable dose for two weeks prior to the dosing visit. Exclusion Criteria: 1. You have a history of psychotic symptoms. 2. You have a history of seizures. 3. You have a current unstable or inadequately treated medical illness, especially cardiovascular illness, except for the current depression. 4. You recently (i.e., within the past 6 weeks) started taking treatment for your acute bipolar depressive episode. 5. You recently (i.e., within the past 8 weeks) began structured psychotherapy (e.g., cognitive-behavioral therapy, interpersonal psychotherapy, family-focused therapy, or interpersonal and social rhythm therapy). 6. You have a history of nonresponse or intolerance to psilocybin. 7. You have, in the past 6 months, used any psychedelic drugs, including ketamine, LSD, or psilocybin-containing mushrooms. 8. You have a history of non-response to electroconvulsive therapy. 9. You are pregnant or lactating.

Inclusion Criteria: * Patients aged ≥ 18 years diagnosed with fibrosing lung disease, obliterative bronchiolitis, or PAH, who are candidates for or have undergone lung transplantation. * Obtaining informed consent for all patients enrolled prospectively and all those enrolled retrospectively at their first clinical occurrence at our center. Exclusion Criteria: * Suspected or confirmed diagnosis of pulmonary neoplastic disease.

Inclusion Criteria: 1. Male or female aged 18 or above; 2. The Eastern Cooperative Oncology Group (ECOG) physical condition score of the United States is ≤2; 3. HER2 positive (IHC 3+ or IHC 2+ and ISH+) confirmed by tumor histology or cytology, and having received one or more anti-HER2 drug treatments previously; Or low expression of HER2 confirmed by tumor histology or cytology (IHC 1+ or IHC 2+ and ISH-), and having received at least one systemic treatment in the metastatic disease stage previously, or unresectable or metastatic breast cancer that relapsed during adjuvant chemotherapy or within 6 months after the completion of adjuvant chemotherapy; 4. Receive goldtrastuzumab treatment in the advanced stage; 5. During the study period, voluntarily abide by this trial protocol and receive regular follow-ups; 6. All women of childbearing age, fertile men or their spouses who have no plans for fertility or sperm donation throughout the trial period until 6 months after the last dose, or who voluntarily take effective contraceptive measures. Exclusion Criteria: 1. Pregnant or lactating women; 2. Those with acute or chronic infections, or those with other serious diseases at the same time, are judged by the researchers as unsuitable for this study; 3. Having suffered from other malignant tumors within 5 years (excluding the following situations: cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary thyroid carcinoma; A second primary cancer that has been completely cured and has no recurrence within five years; Researchers have clearly identified which primary tumor source the metastatic foci belong to. 4. Those with mental illness or mental disorders, poor compliance and inability to cooperate and describe treatment responses; 5. Those with severe organic diseases or major organ failure, such as decompensated heart, lung, liver or kidney failure, which makes them unable to tolerate treatment; 6. Patients allergic to trastuzumab; 7. Patients who changed their treatment regimens after trastuzumab treatment due to reasons other than disease progression or intolerable adverse reactions; 8. The researcher believes that the patient has other circumstances that make them unsuitable for participating in this study

Inclusion Criteria: * Diagnosis of stage 1 hypertension * Regular treatment for more than 6 months * No changes in medication doses during the last 3 months Exclusion Criteria: * Autoimmune diseases * Infectious diseases * Diabetes * Chronic kidney disease * Liver disease * Cancer * AIDS * Pregnant women * Use of catabolic drugs or antibiotics * Use of antioxidant vitamin supplements, prebiotics, probiotics, or synbiotics * Habitual intake of royal jelly * Allergy to bee stings * Acute myocardial infarction (AMI) * Stroke (CVA)

Inclusion Criteria: * patients receiving care at an enrolled site/affiliated Community-Based Outpatient Clinic (CBOC) * report experience of past-year physical, psychological, and/or sexual IPV on an established screening tool used to detect IPV in VHA, and * be able to provide informed consent including permission to have intervention sessions recorded Exclusion Criteria: * severe cognitive impairment, * suicide or homicide intent with a specific plan * untreated or unstable symptoms of mania or psychosis

Inclusion Criteria: * Adults aged 18 years and older at the time of enrollment. There is no upper age limit to ensure inclusivity across age ranges. * A confirmed diagnosis of Idiopathic Intracranial Hypertension, established according to the Dandy criteria. * The diagnostic process must exclude other potential causes of increased intracranial pressure as detailed in the 'Diagnosis' section, ensuring an accurate identification of idiopathic cases. Exclusion Criteria: * A diagnosis other than IIH, specifically: tension-type headache, Chiari I malformation, or any other headache disorder unrelated to IIH. * The presence of secondary causes of increased intracranial pressure (e.g., structural brain abnormalities, venous sinus thrombosis, or medication-induced factors).

Inclusion Criteria: 1. Male and female adults with documented diagnosis of T2D for at least one year. 2. Age \> 18 years of age. 3. Diabetes Distress Scale score \> 2.0 on any DDS subscale. 4. A1c \> 7.5 (with hemoglobin in the normal range). 5. PHQ-9 Depression score \< 15. 6. Stable medical co-morbid conditions. 7. Absence of a psychotic disorder or an intellectual disability. 8. Able to read English. 9. Able to give informed consent. Exclusion Criteria: 1. Male and female adults with documented diagnosis of T2D for less than one year. 2. Age \< 18 years of age. 3. Diabetes Distress Scale score \< 2.0 on all DDS subscales. 4. A1c \< 7.5 (with hemoglobin in the normal range). 5. PHQ-9 Depression score \> 15. 6. Unstable medical co-morbid conditions (e.g., hospitalization in past three months). 7. Presence of a psychotic disorder or an intellectual disability. 8. Initiation of psychotherapy or pharmacotherapy for emotional issues within three months of study entry. 9. Unable to read English. 10. Unable to give informed consent.

Inclusion Criteria: 1. Aged ≥18 years old; ECOG 0 or 1; 2. Patients with HER2 positive or low tumors; 3. Receives neoadjuvant therapy 4. Has adequate cardiac, bone marrow, renal, hepatic and blood clotting functions; 5. Life expectancy \> 3 months - Exclusion Criteria: 1. Significant hepatic or renal dysfunction; 2. Is pregnant or ready to pregnant; 3. Cannot keep their states for half an hour; 4. Refused to join the clinical research; 5. Suffering from claustrophobia or other mental disorders; 6. Any other situation that researchers considered it unsuitable to participate in the trial.

Inclusion Criteria: * Onset of stroke \<6 months ago, or \>6 months since the last stroke event; * Age \>=18 years and \<85 years (as the probability of Vascular Cognitive Impairment increases above 85); * Patients with damage in the middle cerebral artery territory; * NIHSS \>4 and \<26; * mRS score \>=2; * Completion of CT or MRI; * No neurological or psychiatric disorders; no impairment of consciousness; able to comply with relevant treatments; no severe cognitive dysfunction (MMSE \>=15); * All participants are right-handed; Sign the informed consent form. Exclusion Criteria: * History of epilepsy or psychiatric disorders (including depression, anxiety, or schizophrenia); * Severe comorbidities; * History of medication use: benzodiazepines, baclofen, antidepressants; * Non-compliance with the treatment plan; * Acute-phase cerebral hemorrhage, acute infectious diseases; * Severe suicidal tendencies in individuals with depression; * Individuals suffering from severe headaches, high blood pressure, malignant tumors, open wounds, vascular embolism, leukopenia, etc.; * Severe alcohol abuse; * History of cranial surgery, individuals with metal implants in the brain; * Individuals with an implanted cardiac pacemaker; * NIHSS \>26, MMSE \<15; * Any disease likely to prevent the patient from surviving more than one month; * Pregnant individuals.

Inclusion Criteria: * APS Case in APS Region VI- Must have open case * PHQ 9 score- Must have score of nine (9) or more Exclusion Criteria: * Previous mental health diagnosis of bipolar disorder, psychotic disorders, and moderate to severe dementia * Assessment of Consent Proxy- Those who need assessment of consent proxy * Suicidal Intent (as indexed by PhQ-9 question 9)- Those scoring 2 or 3 * Current Alcohol and Drug Dependency- As evidenced by Cut down, Annoyed, Guilty, and Eye-opener (CAGE) score of 3 or more

Inclusion Criteria: * Over 18 years of age * Have a diagnosis of Type 2 diabetes. * Have persistent pain (pain present on more days than not, for 3 months or longer). * Score ≥ 3 on average pain severity on the Brief Pain Inventory (BPI). * Fluent in English * Have access to internet and ability to use a computer over a three month period. Exclusion Criteria: * Under 18 years of age * No diagnosis of Type 2 diabetes * No persistent pain * Not fluent in English * No access to internet nor ability to use a computer.

Inclusion criteria: * Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following: * Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities * Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule * Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc * Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles * Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages * Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue * Large extent of parapapillary atrophy * Reliable and reproducible visual field abnormality considered a valid representation of the subject's functional status * Visual field damage consistent with RNFL damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites) * Visual field loss across the horizontal midline in one hemifield that exceeds loss in the opposite hemifield (in early/ moderate cases) * Absence of other known explanations (e.g. optic disc drusen, optic nerve pit) * Mean diurnal IOP ≥ 18 mmHg and \< 28 mmHg at baseline in at least one eye with an inter-eye IOP difference \< 5 mmHg. * A central corneal thickness (CCT) within the range of 450-650 µm Exclusion criteria: * Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery). * Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \>1 yr prior to baseline. * Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs. * Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence. * Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT. * Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy. * Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study. * Chronic use of any systemic medication for chronic diseases that may affect IOP. * Subjects who are pregnant, lactating or planning a pregnancy. * Any condition in the opinion in the investigator that would potentially confound the results of this study

Inclusion Criteria: * Biologic female * Age between 18 and 50 years old (inclusive) * Clinically premenopausal (defined as having active, regular menstruation without vasomotor symptoms) * At least one of two ovaries readily visualized on diagnostic CT or MR imaging as confirmed by radiologist * Planning to receive radiation therapy (for any indication) * Ability to understand and willingness to sign an IRB-approved written informed consent document. Exclusion Criteria: * Prior pelvic radiation * Prior cancer therapies that are known to impact ovarian function * Prior diagnosis of ovarian insufficiency/failure or menopause * Clinically peri- or post-menopausal * For patients \> 45 years old, if there is a clinical history of vasomotor symptoms OR irregular periods, then the patient must be excluded. * For patients ≤ 45 years old, if there is a history of vasomotor symptoms consistent with menopause OR irregular menstruation for ≥3 months OR recent changes in their menstrual cycle \> 14 days, then the patient must be excluded. * Surgically removed or transposed ovaries * Pregnant and/or breastfeeding

Inclusion Criteria: * 1\) Age 13 - 17 years old; 2)Meet the DSM-5 criteria for MDD with a current MDE without psychotic features, as confirmed by the MINI 3) HAMD-17 total score of ≥20 4) No change in treatment regimen in the 4 weeks prior to screening 5) No severe mental disorders or intellectual disabilities; 6)Can cooperate actively with the experimental process and subsequent follow-up. Exclusion Criteria: * 1\) serious diseases such as heart, liver, kidney and hematopoietic system disorders; 2) abuse drugs or are addicted to alcohol or suffer from uncontrollable mental illnesses; 3) Active suicidal intent, confirmed by the MINI Module B (Suicidality) or HAMD-17 item #3 score ≥3; 4) Pregnant or lactating; 5) Those who have identified definite organic lesions such as infarction foci, softening foci, hemorrhage foci, and space-occupying lesions through plain scan of cranial MRI; 6) Those with implanted objects in the brain (such as aneurysm clips, shunt devices, stimulators, cochlear implants or electrodes) or any other metal objects in or near the head, and cannot be safely removed; 7) Change in medication or psychotherapy treatment regimen before screening 8) Could not cooperate with fMRI examination or tTIS treatment; 9)Have received other forms of brain stimulation treatment in the past 3 months.

Inclusion Criteria: * Voluntary signing of the informed consent form * Female patients aged 18-70 years * Newly diagnosed left-sided breast cancer confirmed by histopathology * No evidence of distant metastasis * Undergoing modified radical mastectomy or breast-conserving surgery * ECOG performance status of 0, 1, or 2 * Tolerance to radiotherapy * Radiation field covering the entire left breast/chest wall ± regional lymphatic drainage area Exclusion Criteria: * Bilateral breast cancer at diagnosis * History of breast reconstruction or implant placement on the affected side * Prior radiotherapy to the chest or supraclavicular region * Patients deemed unsuitable for the study based on the investigator's judgment

Inclusion Criteria: * Adults aged 18-65 * Undergoing acute operative fixation for musculoskeletal trauma * Injury Severity Score (ISS) greater than 15 * Ability to provide informed consent (or consent provided by a legally authorized representative) Exclusion Criteria: * Age under 18 or over 65 * Use of ketamine for preoperative or postoperative sedation * Known allergy or contraindication to ketamine * Prior unsuccessful ketamine therapy for major depressive disorder (MDD) or PTSD * Severe psychiatric conditions or psychotic features * History of dementia or glaucoma * Currently engaged in trauma-focused cognitive behavioral therapy or PTSD psychotherapy started within the past 3 months

Inclusion Criteria: * Children aged between 7 and 11 years * Diagnosed with asthma by a pediatric allergy specialist * Mild or moderate asthma severity according to GINA criteria * No communication difficulties * Have not received any asthma-related education outside of routine clinical care during the study period * No known mental or neurological disabilities * No serious chronic illness other than asthma (e.g., cardiac, neurological conditions) * At least one parent owns a smartphone or tablet * Child and parent volunteer to participate and provide informed consent Exclusion Criteria: * Children younger than 7 or older than 11 * Severe persistent asthma according to GINA criteria * Communication difficulties * Prior asthma education outside of routine clinical care * Children with cognitive or neurological impairments * Children who frequently require emergency care due to asthma exacerbations * Families without access to communication tools (e.g., no internet, smartphone, or unable to communicate) * Lack of consent from either the child or parent